Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Draper Supports FDA's Decision to Reduce Dependence on Animal Testing


News provided by

Draper

Apr 24, 2025, 14:15 ET

Share this article

Share toX

Share this article

Share toX

Draper’s PREDICT96 uses an industry-standard multiwell cell culture plate with 96 individual co-culture devices and a perfusion system driven by 192 microfluidic pumps integrated into the plate lid.
Draper’s PREDICT96 uses an industry-standard multiwell cell culture plate with 96 individual co-culture devices and a perfusion system driven by 192 microfluidic pumps integrated into the plate lid.

Draper announced it is prepared to partner with the FDA and other government agencies to advance the use of microphysiological systems (MPS) and in silico computer models as an alternative to animal testing in the discovery, evaluation and regulatory approval of treatments and vaccines.

CAMBRIDGE, Mass., April 24, 2025 /PRNewswire-PRWeb/ -- Draper today announced it is prepared to partner with the U.S. Food and Drug Administration (FDA) and other government agencies such as the National Institutes of Health (NIH), the Defense Threat Reduction Agency (DTRA), the Biomedical Advanced Research and Development Authority (BARDA), the Defense Health Agency (DHA) and the Department of Veterans Affairs (VA) to advance the acceptance and use of microphysiological systems (MPS) and advanced in silico computer models all focused toward accelerating the discovery, evaluation and regulatory approval of treatments and vaccines.

This is in support of the FDA's announcement on April 10, 2025, that it plans to gradually phase out animal testing requirements for monoclonal antibodies and other drugs. The new approach will employ a range of testing methods, including computational models of toxicity and cell lines using artificial intelligence (AI) and organoid testing in laboratory settings with MPS, also known as organ on a chip. The FDA collectively refers to these as New Approach Methodologies (NAMs).

"Draper is aligned with the FDA's decision to reduce its dependence on animal testing and to utilize the results and insights that NAMs can deliver in the drug testing and evaluation process," said Roger Odegard, Draper's Biodefense/Accelerating MCM Development portfolio lead.

Post this

In addition to reducing animal experimentation, the FDA aims to lower research and development (R&D) costs, and ultimately, drug prices, while ensuring safer therapies reach patients faster.

Roger Odegard, Draper's Biodefense/Accelerating MCM Development portfolio lead said, "Draper is aligned with the FDA's decision to reduce its dependence on animal testing and to utilize the results and insights that NAMs can deliver in the drug testing and evaluation process. With over 20 years of experience developing MPS-based solutions and advanced models for biodefense applications, we fully understand the role in vitro human tissue testing and data intelligence will have when evaluating the safety and effectiveness of drugs, vaccines and antibody-based treatments. And, as a non-profit engineering innovation company, Draper is uniquely positioned to work at the intersection of government, industry and academia to move this initiative forward."

"The FDA's roadmap creates an important opportunity to expand the role of microphysiological systems and related technologies," said Jeffrey Borenstein, Laboratory Fellow at Draper. "Organ models have been around for a while, but their role has been limited to essentially research devices that are incompatible with the pharmaceutical workflow. We at Draper are developing systems that are designed to integrate seamlessly into the drug development workflow, and we have demonstrated in vitro in vivo correlation across a range of high impact applications in disease modeling and safety science. The time for MPS is now, and we are uniquely positioned to meet this moment."

Draper innovations in the MPS space have resulted in a class-leading, high-throughput, tunable organ-on-chip (OOC) microenvironment that can generate physiologically relevant responses in human organ tissue models to accelerate drug discovery, toxicity screening and efficacy testing for therapeutics and vaccines. Draper's flagship MPS architecture – PREDICT96 – has an instrumented microfluidic culture plate (MCP) in the standard 384-well plate footprint that supports 96 individual OOCs or arrayed multi-organ systems simultaneously, with sensors to monitor individual OOCs.

Draper began its MPS development in the early 2000s to improve the understanding of how chemical, biological, radiation and nuclear (CBRN) threats affect the human body and to predict the safety and effectiveness of drugs, vaccines, and antibody-based treatments. Draper advancements in the field have resulted in solutions that leverage human tissue platforms (MPS), immune system models, molecular and cellular assays, omics-based technologies, and advanced analytical methods. These innovations enable in-depth assessment of threat agents and medical countermeasure (MCM) interventions.

In its 25-year history of MPS development, Draper has achieved multiple industry firsts: first to culture mammalian cells in a microfluidic device, first durable multi-organ system, first multiplex instrumented MPS, and first robust MPS in high containment.

Draper has ongoing sponsored work with the Defense Threat Reduction Agency (DTRA) (ETHOS) and the Biomedical Advanced Research and Development Authority (BARDA) (for COVID-CBRN and Filovirus research) that are aligned with FDA's long-term goals and objectives. Additionally, Draper maintains business relationships with world-renowned experts at the nation's leading universities, industry partners, the DoE National Labs, Federally Funded Research and Develop and Centers (FFRDCs), and Contract Research Organizations (CROs) to support FDA's long-term investments and objectives.

Draper is committed to supporting MPS advancement through R&D and innovation, establishing best practices and data standardization, all geared toward accelerating MCM development and testing through a broad team of world-renowned experts. As a non-profit engineering innovation company, Draper is committed to participating in the workgroups and consortia outlined in the FDA's roadmap to reduce animal testing over the next five years.

About Draper
Draper is a non-profit research and development company that solves some of the nation's most important challenges. With more than 2,000 employees working in collaboration across 12 locations, Draper delivers transformative, mission-driven solutions that successfully meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the Draper Scholars program engages with the next generation of innovators while DraperSPARX™ seeks to partner with startups and small businesses that can further our mission. To learn more about Draper, visit http://www.draper.com.

Media Contact

Michael Shirer, Draper, 617-258-2464, [email protected], https://www.draper.com

SOURCE Draper

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.